Schonfeld Strategic Advisors LLC Buys New Position in Qiagen (NYSE:QGEN)

Schonfeld Strategic Advisors LLC bought a new stake in Qiagen (NYSE:QGEN - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 97,231 shares of the company's stock, valued at approximately $4,330,000.

A number of other large investors also recently made changes to their positions in QGEN. AQR Capital Management LLC lifted its position in shares of Qiagen by 40.9% during the 4th quarter. AQR Capital Management LLC now owns 105,303 shares of the company's stock worth $4,689,000 after buying an additional 30,571 shares in the last quarter. Perbak Capital Partners LLP bought a new stake in Qiagen during the fourth quarter worth $1,517,000. Northern Trust Corp boosted its position in Qiagen by 29.5% in the fourth quarter. Northern Trust Corp now owns 1,250,712 shares of the company's stock worth $55,694,000 after purchasing an additional 285,265 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Qiagen by 3.0% in the fourth quarter. The Manufacturers Life Insurance Company now owns 96,482 shares of the company's stock worth $4,322,000 after purchasing an additional 2,832 shares during the last quarter. Finally, Earnest Partners LLC grew its stake in Qiagen by 1.6% in the 4th quarter. Earnest Partners LLC now owns 4,002,489 shares of the company's stock valued at $178,231,000 after purchasing an additional 64,575 shares during the period. 70.00% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on QGEN shares. UBS Group cut their price target on shares of Qiagen from $50.00 to $48.00 and set a "neutral" rating on the stock in a report on Friday, February 7th. Baird R W downgraded Qiagen from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 19th. Redburn Atlantic downgraded Qiagen from a "buy" rating to a "neutral" rating in a research report on Friday, April 4th. Finally, Robert W. Baird upped their price target on Qiagen from $42.00 to $43.00 and gave the company a "neutral" rating in a research report on Monday, April 21st. Seven analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $48.42.

Qiagen Stock Up 0.9 %

Shares of NYSE:QGEN traded up $0.37 during trading on Wednesday, reaching $42.54. The stock had a trading volume of 1,508,488 shares, compared to its average volume of 1,123,877. The firm's 50-day simple moving average is $40.43 and its 200 day simple moving average is $41.73. The company has a market capitalization of $9.46 billion, a P/E ratio of 118.45, a PEG ratio of 2.39 and a beta of 0.67. The company has a current ratio of 3.61, a quick ratio of 3.09 and a debt-to-equity ratio of 0.38. Qiagen has a one year low of $37.63 and a one year high of $49.30.

Qiagen (NYSE:QGEN - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.01. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. As a group, research analysts expect that Qiagen will post 2.26 EPS for the current fiscal year.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.